AVBP vs IOVA
AVBP: Arrivent Biopharma is a clinical-stage oncology company advancing firmonertinib, an EGFR-targeted tyrosine kinase inhibitor for treating non-small cell lung cancer with uncommon mutations, toward pivotal Phase 3 approval. IOVA: Iovance delivers Amtagvi, the first FDA-approved individualized TIL cell therapy for advanced melanoma, with a pipeline expanding to lung cancer and sarcoma through centralized manufacturing and clinical innovation.
Side-by-side fundamentals
| Metric | AVBP | IOVA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $30.44 | $5.17 | |
| Market cap as of 2026-07-23 | $1.3B | $2.3B | |
| Net margin as of 2026-07-23 | n/a | -123.9% | |
| Gross margin as of 2026-07-23 | n/a | +36.7% | |
| Operating margin as of 2026-07-23 | n/a | -127.2% | |
| ROE as of 2026-07-23 | -49.0% | -50.2% | AVBP higher |
| ROA as of 2026-07-23 | -45.4% | -38.8% | IOVA higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | AVBP lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +34.3% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +1388.7% | |
| Beta as of 2026-07-23 | 1.44 | 0.68 | |
| 1-year return as of 2026-07-22 close | +31.1% | +120.1% | IOVA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.